Female Health Company names chief commercial officer
MIAMI — The Female Health Company/Veru Healthcare on Thursday named Brian Groch the company's chief commercial officer. He will report to Mitchell Steiner, president and CEO of The Female Health Company/Veru Healthcare.
“Brian brings an extensive commercial background, having served in senior leadership positions for some of the best known and highly regarded companies in our industry,” stated Steiner. “He has deep experience across multiple therapeutic areas, such as oncology, urology, neurology and cardiology, among others, and an outstanding record of success developing and executing global marketing strategies, generating brand awareness and launching new products."
Groch will be responsible for all sales and marketing activities, with the goal of coordinating prelaunch, launch and sales and marketing activities. He will develop, implement and manage the prescription products infrastructure for the overall commercial organization, including reimbursement, market access, payer policies, sales and marketing, inventory and distribution, trade and customer service.
The initial focus for his team will be to establish the FC2 prescription business infrastructure to produce new and immediate revenue in the U.S., to coordinate the prelaunch and launch activities for Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia and manage the marketing and sales activities for PreBoost, FHC's recently launched proprietary over the counter product for the management of premature ejaculation.
Groch has more than 30 years of experience in the pharmaceutical and biotechnology industries specializing in lobbying health policy change, global sales leadership, marketing, trade and distribution, contract negotiations, presentations and client/patient relations. He most recently served as chief commercial officer of Telesta Therapeutics overseeing the global commercial strategy for the first new biologic for bladder cancer.
Groch began his career at Merck, where he rose through the sales and marketing ranks from 1988 to 2002. He later became head of market access for Dendreon, a biotech company that developed and launched Provenge for metastatic prostate cancer in 2010. In 2013, he was appointed VP market access for Horizon Therapeutics, where he played a key role in building the company’s orphan commercial business capabilities.
Groch earned a Master of Science degree in Healthcare Administration and Marketing and a Bachelor of Science degree in Physiology from Central Michigan University.
Willow introduces hands-free, mobile breast pumping solution
MOUNTAIN VIEW, Calif. — Willow on Thursday introduced a breast pump mobile solution that untethers mom from the wall outlet. The new breast pump fits easily inside a bra, allowing women to achieve their breastfeeding goals without pressing pause on their own lives.
In a proprietary research study by Willow, 89% of moms claimed that their dream pump would be hands-free and wouldn't involve a cumbersome special bra and 67% said their ideal pump wouldn't require them to undress. So Willow designed a pump to fit conveniently into a woman's bra to allow her to pump discreetly while dressed. And for the 44% of moms who wished they didn't have to be connected to a machine that limited their mobility, the Willow pump leaves behind the external tubes, cords and desktop pumps so busy, multi-tasking moms can pump wherever the day takes them.
"We knew there had to be a better solution," said John Chang, chief technology officer for Willow. "We believe in designing with our ears. We listen, really listen to moms and what they need. I am so proud of the Willow team. We are a mission-driven group of mothers, fathers and experienced inventors who created a better solution for moms' needs."
Willow works quietly and discreetly inside a woman's bra, collects milk in an enclosed leak-proof bag and tracks milk volume with an app.
"Current breast pumps require women to step out of life. Willow lets women live their lives," said Naomi Kelman, CEO and president of Willow. "We believe in bringing dignity and humanity to the breast pumping experience, because women shouldn't have to undress or give up who they are – or how they move – to be a mom."
Named with a nod to the willow tree that is strong and nurturing while able to bend to great challenges, Willow is FDA-cleared and will be available this spring with a suggested retail price of $429.
Willow will be unveiled for the first time at the Consumer Electronics Show in Las Vegas during the Baby Tech Summit, as well as appearances at the ShowStoppers and Pepcom/Digital Experience events.
Reliefband set to launch Reliefband Neurowave in early 2017
LAS VEGAS — Reliefband Technologies on Tuesday unveiled its Reliefband Neurowave for the drug-free relief from nausea, retching and vomiting caused by morning sickness and motion sickness, including the motion sickness associated with VR SIM.
"For the 60 million Americans who frequently suffer with motion sickness and the nearly 80% of women who experience morning sickness during pregnancy, the Reliefband Neurowave is simply life-changing," stated Nick Spring, CEO Reliefband Technologies. "The Reliefband Neurowave was developed in response to customers who told us they had given up hope of controlling their nausea," he said. "We wanted to help those who are sick of feeling sick by making a drug-free device that is easy-to-use and elegant to wear over long periods. This way they can start living their lives without the worry, embarrassment, discomfort and inconvenience nausea can bring."
The device allows users to travel without fear of sickness from many common leisure pursuits such as cruising, fishing, amusement rides or staying in the VR game. It will be commercially available in the second quarter of 2017 and will be priced around $150.
The Reliefband Neurowave applies accurately programmed pulses with highly specific waveforms, frequency and intensity to modulate the median nerve on the underside of the wrist. This precise activity (technically referred to as "neuromodulation") uses the body's natural neural pathways to block the waves of nausea produced by the stomach.